Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473697 | 0.76 | CHEK1 (0.56) | PIM1PIM3PIM2WNT1CLK2 | |
| SCHEMBL1561318 | 0.76 | NPC1 (0.39) | MAPTCHEK1ACHEMAP3K8 | |
| SCHEMBL1560453 | 0.76 | DYRK1A (0.46) | PIM1WNT1TGFBR1CLK2CLK3 | |
| SCHEMBL473684 | 0.75 | CHEK1 (0.58) | PIM1PIM3PIM2WNT1CLK2 | |
| SCHEMBL1560506 | 0.75 | PIM1 (0.64) | PIM1PIM3PIM2CLK2CLK3 | |
| SCHEMBL13572727 | 0.74 | CHEK1 (0.43) | MAPTCHEK1ACHEFEN1 | |
| SCHEMBL1559848 | 0.74 | PIM1 (0.40) | PIM1WNT1CLK2DYRK1ACHEK1 | |
| SCHEMBL20685590 | 0.73 | ACHE (0.54) | MAPTMAPK1CHEK1ACHEFEN1 | |
| SCHEMBL473757 | 0.72 | GABRA1 (0.50) | CHEK1ACHE | |
| SCHEMBL473696 | 0.72 | CHEK1 (0.48) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | PIM1 2969/4885PIM3 1240/4885PIM2 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.